This study is in progress, not accepting new patients
A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease
Summary
- Eligibility
- for people ages 12 years and up (full criteria)
- Location
- at UC Irvine UCSF
- Dates
- study startedcompletion around
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Pfizer
- Links
- To obtain contact information for a study center near you, click here.
- ID
- NCT05348915
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- About 147 people participating
- Last Updated